Hata, Aaron N.
Shaw, Alice T.
Article History
First Online: 4 February 2020
Competing interests
: A.N.H. has received research funding from Amgen, Pfizer, Roche/Genentech, Eli Lilly, Novartis and Relay Therapeutics. A.T.S. has served as a compensated consultant or received honoraria from Achilles, Archer, ARIAD, Bayer, Blueprint Medicines, Chugai, Daiichi Sankyo, EMD Serono, Foundation Medicine, Genentech/Roche, Guardant, Ignyta, KSQ Therapeutics, LOXO, Natera, Novartis, Pfizer, Servier, Syros, Taiho Pharmaceutical, Takeda and TP Therapeutics; has received research (institutional) funding from Daiichi Sankyo, Ignyta, Novartis, Pfizer, Roche/Genentech and TP Therapeutics; has served on the Board of Directors of Syros Pharmaceuticals; and is currently an employee of Novartis.